• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

羟甲基化与表观遗传药物:肝细胞癌表观遗传学诊断与治疗新见解

Hydroxymethylation and Epigenetic Drugs: New Insights into the Diagnosis and Treatment in Epigenetics of Hepatocellular Carcinoma.

作者信息

Ouyang Wei, Wang Ming-Da, Wang Wan-Yin, Li Chao, Yao Lan-Qing, Zhu Hong, Yang Tian

机构信息

Department of Medical Oncology, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China.

Department of Hepatobiliary Surgery, Eastern Hepatobiliary Surgery Hospital, Navy Medical University (Second Military Medical University), Shanghai, China.

出版信息

J Oncol. 2023 Feb 9;2023:5449443. doi: 10.1155/2023/5449443. eCollection 2023.

DOI:10.1155/2023/5449443
PMID:36816356
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9934982/
Abstract

Hepatocellular carcinoma (HCC) is a highly lethal and heterogeneous malignancy with multiple genetic alternations and complex signaling pathways. The complexity and multifactorial nature of HCC pose a tremendous challenge regarding its diagnosis and treatment. Emerging evidence has indicated an important regulatory role of epigenetic modifications in HCC initiation and progression. Epigenetic modifications are stably heritable gene expression traits caused by changing the accessibility of chromatin structure and genetic activity without alteration in the DNA sequence and have been gradually recognized as a hallmark of cancer. In addition, accumulating data suggest a potential value of altered hydroxymethylation in epigenetic modifications and therapeutics targeting the epigenetically mediated regulation. As such, probing the epigenetic field in the era of precision oncology is a valid avenue for promoting the accuracy of early diagnosis and improving the oncological prognosis of HCC patients. This review focuses on the diagnostic performance and clinical utility of 5-hydroxymethylated cytosine, the primary intermediate product of the demethylation process, for early HCC diagnosis and discusses the promising applications of epigenetic-based therapeutic regimens for HCC.

摘要

肝细胞癌(HCC)是一种具有高度致死性且异质性的恶性肿瘤,存在多种基因改变和复杂的信号通路。HCC的复杂性和多因素性质对其诊断和治疗构成了巨大挑战。新出现的证据表明表观遗传修饰在HCC的发生和发展中起重要调节作用。表观遗传修饰是由染色质结构可及性和基因活性改变引起的稳定可遗传的基因表达特征,而DNA序列不变,并且已逐渐被视为癌症的一个标志。此外,越来越多的数据表明羟甲基化改变在表观遗传修饰和靶向表观遗传介导调控的治疗中具有潜在价值。因此,在精准肿瘤学时代探索表观遗传领域是提高早期诊断准确性和改善HCC患者肿瘤预后的有效途径。本综述重点关注去甲基化过程的主要中间产物5-羟甲基化胞嘧啶在早期HCC诊断中的诊断性能和临床应用,并讨论基于表观遗传学的治疗方案在HCC中的应用前景。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c9a6/9934982/0342e1e1f98f/JO2023-5449443.002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c9a6/9934982/cece8b28dc5c/JO2023-5449443.001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c9a6/9934982/0342e1e1f98f/JO2023-5449443.002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c9a6/9934982/cece8b28dc5c/JO2023-5449443.001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c9a6/9934982/0342e1e1f98f/JO2023-5449443.002.jpg

相似文献

1
Hydroxymethylation and Epigenetic Drugs: New Insights into the Diagnosis and Treatment in Epigenetics of Hepatocellular Carcinoma.羟甲基化与表观遗传药物:肝细胞癌表观遗传学诊断与治疗新见解
J Oncol. 2023 Feb 9;2023:5449443. doi: 10.1155/2023/5449443. eCollection 2023.
2
Epigenetic remodelling in human hepatocellular carcinoma.人类肝细胞癌中的表观遗传重塑。
J Exp Clin Cancer Res. 2022 Mar 24;41(1):107. doi: 10.1186/s13046-022-02297-2.
3
Genome-wide DNA methylation and hydroxymethylation analysis reveal human menstrual blood-derived stem cells inhibit hepatocellular carcinoma growth through oncogenic pathway suppression via regulating 5-hmC in enhancer elements.全基因组 DNA 甲基化和羟甲基化分析显示,人月经血来源的干细胞通过调节增强子元件中的 5-hmC 抑制致癌通路,从而抑制肝癌生长。
Stem Cell Res Ther. 2019 May 31;10(1):151. doi: 10.1186/s13287-019-1243-8.
4
Epigenetic mechanisms regulating the development of hepatocellular carcinoma and their promise for therapeutics.调控肝细胞癌发生发展的表观遗传机制及其治疗前景。
Hepatol Int. 2017 Jan;11(1):45-53. doi: 10.1007/s12072-016-9743-4. Epub 2016 Jun 7.
5
Dysregulated Epigenetic Modifications in the Pathogenesis of NAFLD-HCC.非酒精性脂肪性肝病相关肝细胞癌发病机制中的表观遗传修饰失调。
Adv Exp Med Biol. 2018;1061:79-93. doi: 10.1007/978-981-10-8684-7_7.
6
Whole-genome DNA methylation and hydroxymethylation profiling for HBV-related hepatocellular carcinoma.乙型肝炎病毒相关肝细胞癌的全基因组DNA甲基化和羟甲基化分析
Int J Oncol. 2016 Aug;49(2):589-602. doi: 10.3892/ijo.2016.3535. Epub 2016 May 24.
7
The potential of DNA modifications as biomarkers and therapeutic targets in oncology.DNA修饰作为肿瘤学中生物标志物和治疗靶点的潜力。
Expert Rev Mol Diagn. 2015;15(10):1325-37. doi: 10.1586/14737159.2015.1084229. Epub 2015 Sep 7.
8
HELLS Regulates Chromatin Remodeling and Epigenetic Silencing of Multiple Tumor Suppressor Genes in Human Hepatocellular Carcinoma.HELLS 调控人肝细胞癌中多个肿瘤抑制基因的染色质重塑和表观遗传沉默。
Hepatology. 2019 May;69(5):2013-2030. doi: 10.1002/hep.30414. Epub 2019 Mar 27.
9
Epigenetics in hepatocellular carcinoma.肝细胞癌中的表观遗传学。
Semin Cancer Biol. 2022 Nov;86(Pt 3):622-632. doi: 10.1016/j.semcancer.2021.07.017. Epub 2021 Jul 26.
10
A novel strategy for the diagnosis, prognosis, treatment, and chemoresistance of hepatocellular carcinoma: DNA methylation.一种用于诊断、预后、治疗和肝癌化疗耐药的新策略:DNA 甲基化。
Med Res Rev. 2020 Sep;40(5):1973-2018. doi: 10.1002/med.21696. Epub 2020 Jun 11.

引用本文的文献

1
IGF2BP2 promotes glycolysis and hepatocellular carcinoma stemness by stabilizing CDC45 mRNA via m6A modification.IGF2BP2通过m6A修饰稳定CDC45 mRNA来促进糖酵解和肝癌干性。
Cell Cycle. 2023 Oct;22(20):2245-2263. doi: 10.1080/15384101.2023.2283328. Epub 2023 Dec 15.

本文引用的文献

1
The Role of Epigenetic Modifications in Human Cancers and the Use of Natural Compounds as Epidrugs: Mechanistic Pathways and Pharmacodynamic Actions.表观遗传学修饰在人类癌症中的作用以及天然化合物作为内源性药物的应用:作用机制和药效学作用。
Biomolecules. 2022 Feb 25;12(3):367. doi: 10.3390/biom12030367.
2
Effect of Zebularine in Comparison to Trichostatin A on the Intrinsic and Extrinsic Apoptotic Pathway, Cell Viability, and Apoptosis in Hepatocellular Carcinoma SK-Hep 1, Human Colorectal Cancer SW620, and Human Pancreatic Cancer PaCa-44 Cell Lines.与曲古抑菌素A相比,泽布替尼对肝癌SK-Hep 1细胞系、人结直肠癌SW620细胞系和人胰腺癌PaCa-44细胞系的内源性和外源性凋亡途径、细胞活力及凋亡的影响
Iran J Pharm Res. 2021 Summer;20(3):310-323. doi: 10.22037/ijpr.2021.115097.15196.
3
Epigenetics in hepatocellular carcinoma.肝细胞癌中的表观遗传学。
Semin Cancer Biol. 2022 Nov;86(Pt 3):622-632. doi: 10.1016/j.semcancer.2021.07.017. Epub 2021 Jul 26.
4
Epigenetic Biomarkers for the Diagnosis and Treatment of Liver Disease.用于肝病诊断和治疗的表观遗传生物标志物
Cancers (Basel). 2021 Mar 12;13(6):1265. doi: 10.3390/cancers13061265.
5
Liquid biopsy by combining 5-hydroxymethylcytosine signatures of plasma cell-free DNA and protein biomarkers for diagnosis and prognosis of hepatocellular carcinoma.通过结合血浆游离 DNA 中 5-羟甲基胞嘧啶特征和蛋白质生物标志物进行液体活检,用于诊断和预测肝细胞癌。
ESMO Open. 2021 Feb;6(1):100021. doi: 10.1016/j.esmoop.2020.100021. Epub 2021 Jan 25.
6
Epigenetics in hepatocellular carcinoma development and therapy: The tip of the iceberg.表观遗传学在肝细胞癌发生发展及治疗中的作用:冰山一角
JHEP Rep. 2020 Aug 7;2(6):100167. doi: 10.1016/j.jhepr.2020.100167. eCollection 2020 Dec.
7
The Contribution of Epigenetics to Cancer Immunotherapy.表观遗传学在癌症免疫治疗中的贡献。
Trends Immunol. 2020 Aug;41(8):676-691. doi: 10.1016/j.it.2020.06.002. Epub 2020 Jul 2.
8
Cancer Epigenetics, Tumor Immunity, and Immunotherapy.癌症表观遗传学、肿瘤免疫与免疫治疗。
Trends Cancer. 2020 Jul;6(7):580-592. doi: 10.1016/j.trecan.2020.02.003. Epub 2020 Mar 31.
9
Towards a more precise therapy in cancer: Exploring epigenetic complexity.朝着癌症更精准的治疗迈进:探索表观遗传学的复杂性。
Curr Opin Chem Biol. 2020 Aug;57:41-49. doi: 10.1016/j.cbpa.2020.04.008. Epub 2020 May 29.
10
The timeline of epigenetic drug discovery: from reality to dreams.表观遗传学药物发现的时间轴:从现实到梦想。
Clin Epigenetics. 2019 Dec 2;11(1):174. doi: 10.1186/s13148-019-0776-0.